Global Mebeverine Market

Mebeverine Comprehensive Study by Type (Tablets, Capsules, Liquid), Application (Abdominal Pain and Cramps, Constipation, Diarrhea, Flatulence), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), End-user (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2026

Mebeverine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Mebeverine Market?

Mebeverine is an antispasmodic medicine used to relieve the symptoms of irritable bowel syndrome (IBS) such as abdominal (tummy) pain and cramps, constipation, diarrhea (runny poos), and flatulence (farting). It comes as tablets or slow-release capsules that relax the tummy muscles and in this way helps to ease bloating and spasm-type pain. The factors such as the Increased Prevalence of Abdominal Diseases among People and the Rise in the Number of Hospitals and Clinics are the drivers for the global Mebeverine market. Also, a Robust Increase in the Distribution Channels are also fueling the growth of the market. However, Side Effects of the Mebeverine may restrain the growth of the Mebeverine market.

The market study is being classified by Type (Tablets, Capsules and Liquid), by Application (Abdominal Pain and Cramps, Constipation, Diarrhea and Flatulence) and major geographies with country level break-up.

Abbott (United States), Mylan N.V. (United States), Berlin Pharmaceutical Industry Co., Ltd. (Thailand), Eipico Pharmaceutical (Egypt), Sopharma (Bulgaria), USV Private Limited (India), PURE Pharma GmbH & Co. KG (Germany), Pharco Corporation (Egypt), Swiss Pharma Pvt Ltd (India) and Dr. Reddy's (India) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Indian Players will contribute to the maximum growth of Global Mebeverine market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Mebeverine market by Type, Application and Region.

On the basis of geography, the market of Mebeverine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Abdominal Diseases among People
  • Rise in the Number of Hospitals and Clinics

Market Trend
  • Robust Increase in the Distribution Channels

Restraints
  • Side Effects of the Mebeverine

Opportunities
  • Growing Number of Geriatric Population
  • Growth in the Healthcare Industry Worldwide

Challenges
  • Stringent Government Rules and Regulation





Key Target Audience
Mebeverine Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • Tablets
  • Capsules
  • Liquid
By Application
  • Abdominal Pain and Cramps
  • Constipation
  • Diarrhea
  • Flatulence
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

By End-user
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Abdominal Diseases among People
      • 3.2.2. Rise in the Number of Hospitals and Clinics
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulation
    • 3.4. Market Trends
      • 3.4.1. Robust Increase in the Distribution Channels
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mebeverine, by Type, Application, Distribution Channel, End-user and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Mebeverine (Value)
      • 5.2.1. Global Mebeverine by: Type (Value)
        • 5.2.1.1. Tablets
        • 5.2.1.2. Capsules
        • 5.2.1.3. Liquid
      • 5.2.2. Global Mebeverine by: Application (Value)
        • 5.2.2.1. Abdominal Pain and Cramps
        • 5.2.2.2. Constipation
        • 5.2.2.3. Diarrhea
        • 5.2.2.4. Flatulence
      • 5.2.3. Global Mebeverine by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online
      • 5.2.4. Global Mebeverine by: End-user (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Others
      • 5.2.5. Global Mebeverine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Mebeverine (Volume)
      • 5.3.1. Global Mebeverine by: Type (Volume)
        • 5.3.1.1. Tablets
        • 5.3.1.2. Capsules
        • 5.3.1.3. Liquid
      • 5.3.2. Global Mebeverine by: Application (Volume)
        • 5.3.2.1. Abdominal Pain and Cramps
        • 5.3.2.2. Constipation
        • 5.3.2.3. Diarrhea
        • 5.3.2.4. Flatulence
      • 5.3.3. Global Mebeverine by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online
      • 5.3.4. Global Mebeverine by: End-user (Volume)
        • 5.3.4.1. Hospitals
        • 5.3.4.2. Clinics
        • 5.3.4.3. Others
      • 5.3.5. Global Mebeverine Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Mebeverine (Price)
      • 5.4.1. Global Mebeverine by: Type (Price)
  • 6. Mebeverine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mylan N.V. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Berlin Pharmaceutical Industry Co., Ltd. (Thailand)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eipico Pharmaceutical (Egypt)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sopharma (Bulgaria)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. USV Private Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. PURE Pharma GmbH & Co. KG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pharco Corporation (Egypt)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Swiss Pharma Pvt Ltd (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Dr. Reddy's (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Mebeverine Sale, by Type, Application, Distribution Channel, End-user and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Mebeverine (Value)
      • 7.2.1. Global Mebeverine by: Type (Value)
        • 7.2.1.1. Tablets
        • 7.2.1.2. Capsules
        • 7.2.1.3. Liquid
      • 7.2.2. Global Mebeverine by: Application (Value)
        • 7.2.2.1. Abdominal Pain and Cramps
        • 7.2.2.2. Constipation
        • 7.2.2.3. Diarrhea
        • 7.2.2.4. Flatulence
      • 7.2.3. Global Mebeverine by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online
      • 7.2.4. Global Mebeverine by: End-user (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Others
      • 7.2.5. Global Mebeverine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Mebeverine (Volume)
      • 7.3.1. Global Mebeverine by: Type (Volume)
        • 7.3.1.1. Tablets
        • 7.3.1.2. Capsules
        • 7.3.1.3. Liquid
      • 7.3.2. Global Mebeverine by: Application (Volume)
        • 7.3.2.1. Abdominal Pain and Cramps
        • 7.3.2.2. Constipation
        • 7.3.2.3. Diarrhea
        • 7.3.2.4. Flatulence
      • 7.3.3. Global Mebeverine by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online
      • 7.3.4. Global Mebeverine by: End-user (Volume)
        • 7.3.4.1. Hospitals
        • 7.3.4.2. Clinics
        • 7.3.4.3. Others
      • 7.3.5. Global Mebeverine Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Mebeverine (Price)
      • 7.4.1. Global Mebeverine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mebeverine: by Type(USD Million)
  • Table 2. Mebeverine Tablets , by Region USD Million (2015-2020)
  • Table 3. Mebeverine Capsules , by Region USD Million (2015-2020)
  • Table 4. Mebeverine Liquid , by Region USD Million (2015-2020)
  • Table 5. Mebeverine: by Application(USD Million)
  • Table 6. Mebeverine Abdominal Pain and Cramps , by Region USD Million (2015-2020)
  • Table 7. Mebeverine Constipation , by Region USD Million (2015-2020)
  • Table 8. Mebeverine Diarrhea , by Region USD Million (2015-2020)
  • Table 9. Mebeverine Flatulence , by Region USD Million (2015-2020)
  • Table 10. Mebeverine: by Distribution Channel(USD Million)
  • Table 11. Mebeverine Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Mebeverine Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 13. Mebeverine Online , by Region USD Million (2015-2020)
  • Table 14. Mebeverine: by End-user(USD Million)
  • Table 15. Mebeverine Hospitals , by Region USD Million (2015-2020)
  • Table 16. Mebeverine Clinics , by Region USD Million (2015-2020)
  • Table 17. Mebeverine Others , by Region USD Million (2015-2020)
  • Table 18. South America Mebeverine, by Country USD Million (2015-2020)
  • Table 19. South America Mebeverine, by Type USD Million (2015-2020)
  • Table 20. South America Mebeverine, by Application USD Million (2015-2020)
  • Table 21. South America Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 22. South America Mebeverine, by End-user USD Million (2015-2020)
  • Table 23. Brazil Mebeverine, by Type USD Million (2015-2020)
  • Table 24. Brazil Mebeverine, by Application USD Million (2015-2020)
  • Table 25. Brazil Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 26. Brazil Mebeverine, by End-user USD Million (2015-2020)
  • Table 27. Argentina Mebeverine, by Type USD Million (2015-2020)
  • Table 28. Argentina Mebeverine, by Application USD Million (2015-2020)
  • Table 29. Argentina Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 30. Argentina Mebeverine, by End-user USD Million (2015-2020)
  • Table 31. Rest of South America Mebeverine, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Mebeverine, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 34. Rest of South America Mebeverine, by End-user USD Million (2015-2020)
  • Table 35. Asia Pacific Mebeverine, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Mebeverine, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Mebeverine, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 39. Asia Pacific Mebeverine, by End-user USD Million (2015-2020)
  • Table 40. China Mebeverine, by Type USD Million (2015-2020)
  • Table 41. China Mebeverine, by Application USD Million (2015-2020)
  • Table 42. China Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 43. China Mebeverine, by End-user USD Million (2015-2020)
  • Table 44. Japan Mebeverine, by Type USD Million (2015-2020)
  • Table 45. Japan Mebeverine, by Application USD Million (2015-2020)
  • Table 46. Japan Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 47. Japan Mebeverine, by End-user USD Million (2015-2020)
  • Table 48. India Mebeverine, by Type USD Million (2015-2020)
  • Table 49. India Mebeverine, by Application USD Million (2015-2020)
  • Table 50. India Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 51. India Mebeverine, by End-user USD Million (2015-2020)
  • Table 52. South Korea Mebeverine, by Type USD Million (2015-2020)
  • Table 53. South Korea Mebeverine, by Application USD Million (2015-2020)
  • Table 54. South Korea Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 55. South Korea Mebeverine, by End-user USD Million (2015-2020)
  • Table 56. Taiwan Mebeverine, by Type USD Million (2015-2020)
  • Table 57. Taiwan Mebeverine, by Application USD Million (2015-2020)
  • Table 58. Taiwan Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 59. Taiwan Mebeverine, by End-user USD Million (2015-2020)
  • Table 60. Australia Mebeverine, by Type USD Million (2015-2020)
  • Table 61. Australia Mebeverine, by Application USD Million (2015-2020)
  • Table 62. Australia Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 63. Australia Mebeverine, by End-user USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Mebeverine, by Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Mebeverine, by Application USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Mebeverine, by End-user USD Million (2015-2020)
  • Table 68. Europe Mebeverine, by Country USD Million (2015-2020)
  • Table 69. Europe Mebeverine, by Type USD Million (2015-2020)
  • Table 70. Europe Mebeverine, by Application USD Million (2015-2020)
  • Table 71. Europe Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 72. Europe Mebeverine, by End-user USD Million (2015-2020)
  • Table 73. Germany Mebeverine, by Type USD Million (2015-2020)
  • Table 74. Germany Mebeverine, by Application USD Million (2015-2020)
  • Table 75. Germany Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 76. Germany Mebeverine, by End-user USD Million (2015-2020)
  • Table 77. France Mebeverine, by Type USD Million (2015-2020)
  • Table 78. France Mebeverine, by Application USD Million (2015-2020)
  • Table 79. France Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 80. France Mebeverine, by End-user USD Million (2015-2020)
  • Table 81. Italy Mebeverine, by Type USD Million (2015-2020)
  • Table 82. Italy Mebeverine, by Application USD Million (2015-2020)
  • Table 83. Italy Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 84. Italy Mebeverine, by End-user USD Million (2015-2020)
  • Table 85. United Kingdom Mebeverine, by Type USD Million (2015-2020)
  • Table 86. United Kingdom Mebeverine, by Application USD Million (2015-2020)
  • Table 87. United Kingdom Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 88. United Kingdom Mebeverine, by End-user USD Million (2015-2020)
  • Table 89. Netherlands Mebeverine, by Type USD Million (2015-2020)
  • Table 90. Netherlands Mebeverine, by Application USD Million (2015-2020)
  • Table 91. Netherlands Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 92. Netherlands Mebeverine, by End-user USD Million (2015-2020)
  • Table 93. Rest of Europe Mebeverine, by Type USD Million (2015-2020)
  • Table 94. Rest of Europe Mebeverine, by Application USD Million (2015-2020)
  • Table 95. Rest of Europe Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 96. Rest of Europe Mebeverine, by End-user USD Million (2015-2020)
  • Table 97. MEA Mebeverine, by Country USD Million (2015-2020)
  • Table 98. MEA Mebeverine, by Type USD Million (2015-2020)
  • Table 99. MEA Mebeverine, by Application USD Million (2015-2020)
  • Table 100. MEA Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 101. MEA Mebeverine, by End-user USD Million (2015-2020)
  • Table 102. Middle East Mebeverine, by Type USD Million (2015-2020)
  • Table 103. Middle East Mebeverine, by Application USD Million (2015-2020)
  • Table 104. Middle East Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 105. Middle East Mebeverine, by End-user USD Million (2015-2020)
  • Table 106. Africa Mebeverine, by Type USD Million (2015-2020)
  • Table 107. Africa Mebeverine, by Application USD Million (2015-2020)
  • Table 108. Africa Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 109. Africa Mebeverine, by End-user USD Million (2015-2020)
  • Table 110. North America Mebeverine, by Country USD Million (2015-2020)
  • Table 111. North America Mebeverine, by Type USD Million (2015-2020)
  • Table 112. North America Mebeverine, by Application USD Million (2015-2020)
  • Table 113. North America Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 114. North America Mebeverine, by End-user USD Million (2015-2020)
  • Table 115. United States Mebeverine, by Type USD Million (2015-2020)
  • Table 116. United States Mebeverine, by Application USD Million (2015-2020)
  • Table 117. United States Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 118. United States Mebeverine, by End-user USD Million (2015-2020)
  • Table 119. Canada Mebeverine, by Type USD Million (2015-2020)
  • Table 120. Canada Mebeverine, by Application USD Million (2015-2020)
  • Table 121. Canada Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 122. Canada Mebeverine, by End-user USD Million (2015-2020)
  • Table 123. Mexico Mebeverine, by Type USD Million (2015-2020)
  • Table 124. Mexico Mebeverine, by Application USD Million (2015-2020)
  • Table 125. Mexico Mebeverine, by Distribution Channel USD Million (2015-2020)
  • Table 126. Mexico Mebeverine, by End-user USD Million (2015-2020)
  • Table 127. Mebeverine Sales: by Type(K Units)
  • Table 128. Mebeverine Sales Tablets , by Region K Units (2015-2020)
  • Table 129. Mebeverine Sales Capsules , by Region K Units (2015-2020)
  • Table 130. Mebeverine Sales Liquid , by Region K Units (2015-2020)
  • Table 131. Mebeverine Sales: by Application(K Units)
  • Table 132. Mebeverine Sales Abdominal Pain and Cramps , by Region K Units (2015-2020)
  • Table 133. Mebeverine Sales Constipation , by Region K Units (2015-2020)
  • Table 134. Mebeverine Sales Diarrhea , by Region K Units (2015-2020)
  • Table 135. Mebeverine Sales Flatulence , by Region K Units (2015-2020)
  • Table 136. Mebeverine Sales: by Distribution Channel(K Units)
  • Table 137. Mebeverine Sales Hospital Pharmacies , by Region K Units (2015-2020)
  • Table 138. Mebeverine Sales Retail Pharmacies , by Region K Units (2015-2020)
  • Table 139. Mebeverine Sales Online , by Region K Units (2015-2020)
  • Table 140. Mebeverine Sales: by End-user(K Units)
  • Table 141. Mebeverine Sales Hospitals , by Region K Units (2015-2020)
  • Table 142. Mebeverine Sales Clinics , by Region K Units (2015-2020)
  • Table 143. Mebeverine Sales Others , by Region K Units (2015-2020)
  • Table 144. South America Mebeverine Sales, by Country K Units (2015-2020)
  • Table 145. South America Mebeverine Sales, by Type K Units (2015-2020)
  • Table 146. South America Mebeverine Sales, by Application K Units (2015-2020)
  • Table 147. South America Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 148. South America Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 149. Brazil Mebeverine Sales, by Type K Units (2015-2020)
  • Table 150. Brazil Mebeverine Sales, by Application K Units (2015-2020)
  • Table 151. Brazil Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 152. Brazil Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 153. Argentina Mebeverine Sales, by Type K Units (2015-2020)
  • Table 154. Argentina Mebeverine Sales, by Application K Units (2015-2020)
  • Table 155. Argentina Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 156. Argentina Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 157. Rest of South America Mebeverine Sales, by Type K Units (2015-2020)
  • Table 158. Rest of South America Mebeverine Sales, by Application K Units (2015-2020)
  • Table 159. Rest of South America Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 160. Rest of South America Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 161. Asia Pacific Mebeverine Sales, by Country K Units (2015-2020)
  • Table 162. Asia Pacific Mebeverine Sales, by Type K Units (2015-2020)
  • Table 163. Asia Pacific Mebeverine Sales, by Application K Units (2015-2020)
  • Table 164. Asia Pacific Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 165. Asia Pacific Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 166. China Mebeverine Sales, by Type K Units (2015-2020)
  • Table 167. China Mebeverine Sales, by Application K Units (2015-2020)
  • Table 168. China Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 169. China Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 170. Japan Mebeverine Sales, by Type K Units (2015-2020)
  • Table 171. Japan Mebeverine Sales, by Application K Units (2015-2020)
  • Table 172. Japan Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 173. Japan Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 174. India Mebeverine Sales, by Type K Units (2015-2020)
  • Table 175. India Mebeverine Sales, by Application K Units (2015-2020)
  • Table 176. India Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 177. India Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 178. South Korea Mebeverine Sales, by Type K Units (2015-2020)
  • Table 179. South Korea Mebeverine Sales, by Application K Units (2015-2020)
  • Table 180. South Korea Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 181. South Korea Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 182. Taiwan Mebeverine Sales, by Type K Units (2015-2020)
  • Table 183. Taiwan Mebeverine Sales, by Application K Units (2015-2020)
  • Table 184. Taiwan Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 185. Taiwan Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 186. Australia Mebeverine Sales, by Type K Units (2015-2020)
  • Table 187. Australia Mebeverine Sales, by Application K Units (2015-2020)
  • Table 188. Australia Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 189. Australia Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 190. Rest of Asia-Pacific Mebeverine Sales, by Type K Units (2015-2020)
  • Table 191. Rest of Asia-Pacific Mebeverine Sales, by Application K Units (2015-2020)
  • Table 192. Rest of Asia-Pacific Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 193. Rest of Asia-Pacific Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 194. Europe Mebeverine Sales, by Country K Units (2015-2020)
  • Table 195. Europe Mebeverine Sales, by Type K Units (2015-2020)
  • Table 196. Europe Mebeverine Sales, by Application K Units (2015-2020)
  • Table 197. Europe Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 198. Europe Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 199. Germany Mebeverine Sales, by Type K Units (2015-2020)
  • Table 200. Germany Mebeverine Sales, by Application K Units (2015-2020)
  • Table 201. Germany Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 202. Germany Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 203. France Mebeverine Sales, by Type K Units (2015-2020)
  • Table 204. France Mebeverine Sales, by Application K Units (2015-2020)
  • Table 205. France Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 206. France Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 207. Italy Mebeverine Sales, by Type K Units (2015-2020)
  • Table 208. Italy Mebeverine Sales, by Application K Units (2015-2020)
  • Table 209. Italy Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 210. Italy Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 211. United Kingdom Mebeverine Sales, by Type K Units (2015-2020)
  • Table 212. United Kingdom Mebeverine Sales, by Application K Units (2015-2020)
  • Table 213. United Kingdom Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 214. United Kingdom Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 215. Netherlands Mebeverine Sales, by Type K Units (2015-2020)
  • Table 216. Netherlands Mebeverine Sales, by Application K Units (2015-2020)
  • Table 217. Netherlands Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 218. Netherlands Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 219. Rest of Europe Mebeverine Sales, by Type K Units (2015-2020)
  • Table 220. Rest of Europe Mebeverine Sales, by Application K Units (2015-2020)
  • Table 221. Rest of Europe Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 222. Rest of Europe Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 223. MEA Mebeverine Sales, by Country K Units (2015-2020)
  • Table 224. MEA Mebeverine Sales, by Type K Units (2015-2020)
  • Table 225. MEA Mebeverine Sales, by Application K Units (2015-2020)
  • Table 226. MEA Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 227. MEA Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 228. Middle East Mebeverine Sales, by Type K Units (2015-2020)
  • Table 229. Middle East Mebeverine Sales, by Application K Units (2015-2020)
  • Table 230. Middle East Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 231. Middle East Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 232. Africa Mebeverine Sales, by Type K Units (2015-2020)
  • Table 233. Africa Mebeverine Sales, by Application K Units (2015-2020)
  • Table 234. Africa Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 235. Africa Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 236. North America Mebeverine Sales, by Country K Units (2015-2020)
  • Table 237. North America Mebeverine Sales, by Type K Units (2015-2020)
  • Table 238. North America Mebeverine Sales, by Application K Units (2015-2020)
  • Table 239. North America Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 240. North America Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 241. United States Mebeverine Sales, by Type K Units (2015-2020)
  • Table 242. United States Mebeverine Sales, by Application K Units (2015-2020)
  • Table 243. United States Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 244. United States Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 245. Canada Mebeverine Sales, by Type K Units (2015-2020)
  • Table 246. Canada Mebeverine Sales, by Application K Units (2015-2020)
  • Table 247. Canada Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 248. Canada Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 249. Mexico Mebeverine Sales, by Type K Units (2015-2020)
  • Table 250. Mexico Mebeverine Sales, by Application K Units (2015-2020)
  • Table 251. Mexico Mebeverine Sales, by Distribution Channel K Units (2015-2020)
  • Table 252. Mexico Mebeverine Sales, by End-user K Units (2015-2020)
  • Table 253. Mebeverine: by Type(USD/Units)
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Mebeverine: by Type(USD Million)
  • Table 265. Mebeverine Tablets , by Region USD Million (2021-2026)
  • Table 266. Mebeverine Capsules , by Region USD Million (2021-2026)
  • Table 267. Mebeverine Liquid , by Region USD Million (2021-2026)
  • Table 268. Mebeverine: by Application(USD Million)
  • Table 269. Mebeverine Abdominal Pain and Cramps , by Region USD Million (2021-2026)
  • Table 270. Mebeverine Constipation , by Region USD Million (2021-2026)
  • Table 271. Mebeverine Diarrhea , by Region USD Million (2021-2026)
  • Table 272. Mebeverine Flatulence , by Region USD Million (2021-2026)
  • Table 273. Mebeverine: by Distribution Channel(USD Million)
  • Table 274. Mebeverine Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 275. Mebeverine Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 276. Mebeverine Online , by Region USD Million (2021-2026)
  • Table 277. Mebeverine: by End-user(USD Million)
  • Table 278. Mebeverine Hospitals , by Region USD Million (2021-2026)
  • Table 279. Mebeverine Clinics , by Region USD Million (2021-2026)
  • Table 280. Mebeverine Others , by Region USD Million (2021-2026)
  • Table 281. South America Mebeverine, by Country USD Million (2021-2026)
  • Table 282. South America Mebeverine, by Type USD Million (2021-2026)
  • Table 283. South America Mebeverine, by Application USD Million (2021-2026)
  • Table 284. South America Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 285. South America Mebeverine, by End-user USD Million (2021-2026)
  • Table 286. Brazil Mebeverine, by Type USD Million (2021-2026)
  • Table 287. Brazil Mebeverine, by Application USD Million (2021-2026)
  • Table 288. Brazil Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 289. Brazil Mebeverine, by End-user USD Million (2021-2026)
  • Table 290. Argentina Mebeverine, by Type USD Million (2021-2026)
  • Table 291. Argentina Mebeverine, by Application USD Million (2021-2026)
  • Table 292. Argentina Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 293. Argentina Mebeverine, by End-user USD Million (2021-2026)
  • Table 294. Rest of South America Mebeverine, by Type USD Million (2021-2026)
  • Table 295. Rest of South America Mebeverine, by Application USD Million (2021-2026)
  • Table 296. Rest of South America Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 297. Rest of South America Mebeverine, by End-user USD Million (2021-2026)
  • Table 298. Asia Pacific Mebeverine, by Country USD Million (2021-2026)
  • Table 299. Asia Pacific Mebeverine, by Type USD Million (2021-2026)
  • Table 300. Asia Pacific Mebeverine, by Application USD Million (2021-2026)
  • Table 301. Asia Pacific Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 302. Asia Pacific Mebeverine, by End-user USD Million (2021-2026)
  • Table 303. China Mebeverine, by Type USD Million (2021-2026)
  • Table 304. China Mebeverine, by Application USD Million (2021-2026)
  • Table 305. China Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 306. China Mebeverine, by End-user USD Million (2021-2026)
  • Table 307. Japan Mebeverine, by Type USD Million (2021-2026)
  • Table 308. Japan Mebeverine, by Application USD Million (2021-2026)
  • Table 309. Japan Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 310. Japan Mebeverine, by End-user USD Million (2021-2026)
  • Table 311. India Mebeverine, by Type USD Million (2021-2026)
  • Table 312. India Mebeverine, by Application USD Million (2021-2026)
  • Table 313. India Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 314. India Mebeverine, by End-user USD Million (2021-2026)
  • Table 315. South Korea Mebeverine, by Type USD Million (2021-2026)
  • Table 316. South Korea Mebeverine, by Application USD Million (2021-2026)
  • Table 317. South Korea Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 318. South Korea Mebeverine, by End-user USD Million (2021-2026)
  • Table 319. Taiwan Mebeverine, by Type USD Million (2021-2026)
  • Table 320. Taiwan Mebeverine, by Application USD Million (2021-2026)
  • Table 321. Taiwan Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 322. Taiwan Mebeverine, by End-user USD Million (2021-2026)
  • Table 323. Australia Mebeverine, by Type USD Million (2021-2026)
  • Table 324. Australia Mebeverine, by Application USD Million (2021-2026)
  • Table 325. Australia Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 326. Australia Mebeverine, by End-user USD Million (2021-2026)
  • Table 327. Rest of Asia-Pacific Mebeverine, by Type USD Million (2021-2026)
  • Table 328. Rest of Asia-Pacific Mebeverine, by Application USD Million (2021-2026)
  • Table 329. Rest of Asia-Pacific Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 330. Rest of Asia-Pacific Mebeverine, by End-user USD Million (2021-2026)
  • Table 331. Europe Mebeverine, by Country USD Million (2021-2026)
  • Table 332. Europe Mebeverine, by Type USD Million (2021-2026)
  • Table 333. Europe Mebeverine, by Application USD Million (2021-2026)
  • Table 334. Europe Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 335. Europe Mebeverine, by End-user USD Million (2021-2026)
  • Table 336. Germany Mebeverine, by Type USD Million (2021-2026)
  • Table 337. Germany Mebeverine, by Application USD Million (2021-2026)
  • Table 338. Germany Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 339. Germany Mebeverine, by End-user USD Million (2021-2026)
  • Table 340. France Mebeverine, by Type USD Million (2021-2026)
  • Table 341. France Mebeverine, by Application USD Million (2021-2026)
  • Table 342. France Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 343. France Mebeverine, by End-user USD Million (2021-2026)
  • Table 344. Italy Mebeverine, by Type USD Million (2021-2026)
  • Table 345. Italy Mebeverine, by Application USD Million (2021-2026)
  • Table 346. Italy Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 347. Italy Mebeverine, by End-user USD Million (2021-2026)
  • Table 348. United Kingdom Mebeverine, by Type USD Million (2021-2026)
  • Table 349. United Kingdom Mebeverine, by Application USD Million (2021-2026)
  • Table 350. United Kingdom Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 351. United Kingdom Mebeverine, by End-user USD Million (2021-2026)
  • Table 352. Netherlands Mebeverine, by Type USD Million (2021-2026)
  • Table 353. Netherlands Mebeverine, by Application USD Million (2021-2026)
  • Table 354. Netherlands Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 355. Netherlands Mebeverine, by End-user USD Million (2021-2026)
  • Table 356. Rest of Europe Mebeverine, by Type USD Million (2021-2026)
  • Table 357. Rest of Europe Mebeverine, by Application USD Million (2021-2026)
  • Table 358. Rest of Europe Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 359. Rest of Europe Mebeverine, by End-user USD Million (2021-2026)
  • Table 360. MEA Mebeverine, by Country USD Million (2021-2026)
  • Table 361. MEA Mebeverine, by Type USD Million (2021-2026)
  • Table 362. MEA Mebeverine, by Application USD Million (2021-2026)
  • Table 363. MEA Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 364. MEA Mebeverine, by End-user USD Million (2021-2026)
  • Table 365. Middle East Mebeverine, by Type USD Million (2021-2026)
  • Table 366. Middle East Mebeverine, by Application USD Million (2021-2026)
  • Table 367. Middle East Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 368. Middle East Mebeverine, by End-user USD Million (2021-2026)
  • Table 369. Africa Mebeverine, by Type USD Million (2021-2026)
  • Table 370. Africa Mebeverine, by Application USD Million (2021-2026)
  • Table 371. Africa Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 372. Africa Mebeverine, by End-user USD Million (2021-2026)
  • Table 373. North America Mebeverine, by Country USD Million (2021-2026)
  • Table 374. North America Mebeverine, by Type USD Million (2021-2026)
  • Table 375. North America Mebeverine, by Application USD Million (2021-2026)
  • Table 376. North America Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 377. North America Mebeverine, by End-user USD Million (2021-2026)
  • Table 378. United States Mebeverine, by Type USD Million (2021-2026)
  • Table 379. United States Mebeverine, by Application USD Million (2021-2026)
  • Table 380. United States Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 381. United States Mebeverine, by End-user USD Million (2021-2026)
  • Table 382. Canada Mebeverine, by Type USD Million (2021-2026)
  • Table 383. Canada Mebeverine, by Application USD Million (2021-2026)
  • Table 384. Canada Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 385. Canada Mebeverine, by End-user USD Million (2021-2026)
  • Table 386. Mexico Mebeverine, by Type USD Million (2021-2026)
  • Table 387. Mexico Mebeverine, by Application USD Million (2021-2026)
  • Table 388. Mexico Mebeverine, by Distribution Channel USD Million (2021-2026)
  • Table 389. Mexico Mebeverine, by End-user USD Million (2021-2026)
  • Table 390. Mebeverine Sales: by Type(K Units)
  • Table 391. Mebeverine Sales Tablets , by Region K Units (2021-2026)
  • Table 392. Mebeverine Sales Capsules , by Region K Units (2021-2026)
  • Table 393. Mebeverine Sales Liquid , by Region K Units (2021-2026)
  • Table 394. Mebeverine Sales: by Application(K Units)
  • Table 395. Mebeverine Sales Abdominal Pain and Cramps , by Region K Units (2021-2026)
  • Table 396. Mebeverine Sales Constipation , by Region K Units (2021-2026)
  • Table 397. Mebeverine Sales Diarrhea , by Region K Units (2021-2026)
  • Table 398. Mebeverine Sales Flatulence , by Region K Units (2021-2026)
  • Table 399. Mebeverine Sales: by Distribution Channel(K Units)
  • Table 400. Mebeverine Sales Hospital Pharmacies , by Region K Units (2021-2026)
  • Table 401. Mebeverine Sales Retail Pharmacies , by Region K Units (2021-2026)
  • Table 402. Mebeverine Sales Online , by Region K Units (2021-2026)
  • Table 403. Mebeverine Sales: by End-user(K Units)
  • Table 404. Mebeverine Sales Hospitals , by Region K Units (2021-2026)
  • Table 405. Mebeverine Sales Clinics , by Region K Units (2021-2026)
  • Table 406. Mebeverine Sales Others , by Region K Units (2021-2026)
  • Table 407. South America Mebeverine Sales, by Country K Units (2021-2026)
  • Table 408. South America Mebeverine Sales, by Type K Units (2021-2026)
  • Table 409. South America Mebeverine Sales, by Application K Units (2021-2026)
  • Table 410. South America Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 411. South America Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 412. Brazil Mebeverine Sales, by Type K Units (2021-2026)
  • Table 413. Brazil Mebeverine Sales, by Application K Units (2021-2026)
  • Table 414. Brazil Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 415. Brazil Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 416. Argentina Mebeverine Sales, by Type K Units (2021-2026)
  • Table 417. Argentina Mebeverine Sales, by Application K Units (2021-2026)
  • Table 418. Argentina Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 419. Argentina Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 420. Rest of South America Mebeverine Sales, by Type K Units (2021-2026)
  • Table 421. Rest of South America Mebeverine Sales, by Application K Units (2021-2026)
  • Table 422. Rest of South America Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 423. Rest of South America Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 424. Asia Pacific Mebeverine Sales, by Country K Units (2021-2026)
  • Table 425. Asia Pacific Mebeverine Sales, by Type K Units (2021-2026)
  • Table 426. Asia Pacific Mebeverine Sales, by Application K Units (2021-2026)
  • Table 427. Asia Pacific Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 428. Asia Pacific Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 429. China Mebeverine Sales, by Type K Units (2021-2026)
  • Table 430. China Mebeverine Sales, by Application K Units (2021-2026)
  • Table 431. China Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 432. China Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 433. Japan Mebeverine Sales, by Type K Units (2021-2026)
  • Table 434. Japan Mebeverine Sales, by Application K Units (2021-2026)
  • Table 435. Japan Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 436. Japan Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 437. India Mebeverine Sales, by Type K Units (2021-2026)
  • Table 438. India Mebeverine Sales, by Application K Units (2021-2026)
  • Table 439. India Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 440. India Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 441. South Korea Mebeverine Sales, by Type K Units (2021-2026)
  • Table 442. South Korea Mebeverine Sales, by Application K Units (2021-2026)
  • Table 443. South Korea Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 444. South Korea Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 445. Taiwan Mebeverine Sales, by Type K Units (2021-2026)
  • Table 446. Taiwan Mebeverine Sales, by Application K Units (2021-2026)
  • Table 447. Taiwan Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 448. Taiwan Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 449. Australia Mebeverine Sales, by Type K Units (2021-2026)
  • Table 450. Australia Mebeverine Sales, by Application K Units (2021-2026)
  • Table 451. Australia Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 452. Australia Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 453. Rest of Asia-Pacific Mebeverine Sales, by Type K Units (2021-2026)
  • Table 454. Rest of Asia-Pacific Mebeverine Sales, by Application K Units (2021-2026)
  • Table 455. Rest of Asia-Pacific Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 456. Rest of Asia-Pacific Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 457. Europe Mebeverine Sales, by Country K Units (2021-2026)
  • Table 458. Europe Mebeverine Sales, by Type K Units (2021-2026)
  • Table 459. Europe Mebeverine Sales, by Application K Units (2021-2026)
  • Table 460. Europe Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 461. Europe Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 462. Germany Mebeverine Sales, by Type K Units (2021-2026)
  • Table 463. Germany Mebeverine Sales, by Application K Units (2021-2026)
  • Table 464. Germany Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 465. Germany Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 466. France Mebeverine Sales, by Type K Units (2021-2026)
  • Table 467. France Mebeverine Sales, by Application K Units (2021-2026)
  • Table 468. France Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 469. France Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 470. Italy Mebeverine Sales, by Type K Units (2021-2026)
  • Table 471. Italy Mebeverine Sales, by Application K Units (2021-2026)
  • Table 472. Italy Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 473. Italy Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 474. United Kingdom Mebeverine Sales, by Type K Units (2021-2026)
  • Table 475. United Kingdom Mebeverine Sales, by Application K Units (2021-2026)
  • Table 476. United Kingdom Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 477. United Kingdom Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 478. Netherlands Mebeverine Sales, by Type K Units (2021-2026)
  • Table 479. Netherlands Mebeverine Sales, by Application K Units (2021-2026)
  • Table 480. Netherlands Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 481. Netherlands Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 482. Rest of Europe Mebeverine Sales, by Type K Units (2021-2026)
  • Table 483. Rest of Europe Mebeverine Sales, by Application K Units (2021-2026)
  • Table 484. Rest of Europe Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 485. Rest of Europe Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 486. MEA Mebeverine Sales, by Country K Units (2021-2026)
  • Table 487. MEA Mebeverine Sales, by Type K Units (2021-2026)
  • Table 488. MEA Mebeverine Sales, by Application K Units (2021-2026)
  • Table 489. MEA Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 490. MEA Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 491. Middle East Mebeverine Sales, by Type K Units (2021-2026)
  • Table 492. Middle East Mebeverine Sales, by Application K Units (2021-2026)
  • Table 493. Middle East Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 494. Middle East Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 495. Africa Mebeverine Sales, by Type K Units (2021-2026)
  • Table 496. Africa Mebeverine Sales, by Application K Units (2021-2026)
  • Table 497. Africa Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 498. Africa Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 499. North America Mebeverine Sales, by Country K Units (2021-2026)
  • Table 500. North America Mebeverine Sales, by Type K Units (2021-2026)
  • Table 501. North America Mebeverine Sales, by Application K Units (2021-2026)
  • Table 502. North America Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 503. North America Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 504. United States Mebeverine Sales, by Type K Units (2021-2026)
  • Table 505. United States Mebeverine Sales, by Application K Units (2021-2026)
  • Table 506. United States Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 507. United States Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 508. Canada Mebeverine Sales, by Type K Units (2021-2026)
  • Table 509. Canada Mebeverine Sales, by Application K Units (2021-2026)
  • Table 510. Canada Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 511. Canada Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 512. Mexico Mebeverine Sales, by Type K Units (2021-2026)
  • Table 513. Mexico Mebeverine Sales, by Application K Units (2021-2026)
  • Table 514. Mexico Mebeverine Sales, by Distribution Channel K Units (2021-2026)
  • Table 515. Mexico Mebeverine Sales, by End-user K Units (2021-2026)
  • Table 516. Mebeverine: by Type(USD/Units)
  • Table 517. Research Programs/Design for This Report
  • Table 518. Key Data Information from Secondary Sources
  • Table 519. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mebeverine: by Type USD Million (2015-2020)
  • Figure 5. Global Mebeverine: by Application USD Million (2015-2020)
  • Figure 6. Global Mebeverine: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Mebeverine: by End-user USD Million (2015-2020)
  • Figure 8. South America Mebeverine Share (%), by Country
  • Figure 9. Asia Pacific Mebeverine Share (%), by Country
  • Figure 10. Europe Mebeverine Share (%), by Country
  • Figure 11. MEA Mebeverine Share (%), by Country
  • Figure 12. North America Mebeverine Share (%), by Country
  • Figure 13. Global Mebeverine: by Type K Units (2015-2020)
  • Figure 14. Global Mebeverine: by Application K Units (2015-2020)
  • Figure 15. Global Mebeverine: by Distribution Channel K Units (2015-2020)
  • Figure 16. Global Mebeverine: by End-user K Units (2015-2020)
  • Figure 17. South America Mebeverine Share (%), by Country
  • Figure 18. Asia Pacific Mebeverine Share (%), by Country
  • Figure 19. Europe Mebeverine Share (%), by Country
  • Figure 20. MEA Mebeverine Share (%), by Country
  • Figure 21. North America Mebeverine Share (%), by Country
  • Figure 22. Global Mebeverine: by Type USD/Units (2015-2020)
  • Figure 23. Global Mebeverine share by Players 2020 (%)
  • Figure 24. Global Mebeverine share by Players (Top 3) 2020(%)
  • Figure 25. Global Mebeverine share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 28. Abbott (United States) Revenue: by Geography 2020
  • Figure 29. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 31. Berlin Pharmaceutical Industry Co., Ltd. (Thailand) Revenue, Net Income and Gross profit
  • Figure 32. Berlin Pharmaceutical Industry Co., Ltd. (Thailand) Revenue: by Geography 2020
  • Figure 33. Eipico Pharmaceutical (Egypt) Revenue, Net Income and Gross profit
  • Figure 34. Eipico Pharmaceutical (Egypt) Revenue: by Geography 2020
  • Figure 35. Sopharma (Bulgaria) Revenue, Net Income and Gross profit
  • Figure 36. Sopharma (Bulgaria) Revenue: by Geography 2020
  • Figure 37. USV Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 38. USV Private Limited (India) Revenue: by Geography 2020
  • Figure 39. PURE Pharma GmbH & Co. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 40. PURE Pharma GmbH & Co. KG (Germany) Revenue: by Geography 2020
  • Figure 41. Pharco Corporation (Egypt) Revenue, Net Income and Gross profit
  • Figure 42. Pharco Corporation (Egypt) Revenue: by Geography 2020
  • Figure 43. Swiss Pharma Pvt Ltd (India) Revenue, Net Income and Gross profit
  • Figure 44. Swiss Pharma Pvt Ltd (India) Revenue: by Geography 2020
  • Figure 45. Dr. Reddy's (India) Revenue, Net Income and Gross profit
  • Figure 46. Dr. Reddy's (India) Revenue: by Geography 2020
  • Figure 47. Global Mebeverine: by Type USD Million (2021-2026)
  • Figure 48. Global Mebeverine: by Application USD Million (2021-2026)
  • Figure 49. Global Mebeverine: by Distribution Channel USD Million (2021-2026)
  • Figure 50. Global Mebeverine: by End-user USD Million (2021-2026)
  • Figure 51. South America Mebeverine Share (%), by Country
  • Figure 52. Asia Pacific Mebeverine Share (%), by Country
  • Figure 53. Europe Mebeverine Share (%), by Country
  • Figure 54. MEA Mebeverine Share (%), by Country
  • Figure 55. North America Mebeverine Share (%), by Country
  • Figure 56. Global Mebeverine: by Type K Units (2021-2026)
  • Figure 57. Global Mebeverine: by Application K Units (2021-2026)
  • Figure 58. Global Mebeverine: by Distribution Channel K Units (2021-2026)
  • Figure 59. Global Mebeverine: by End-user K Units (2021-2026)
  • Figure 60. South America Mebeverine Share (%), by Country
  • Figure 61. Asia Pacific Mebeverine Share (%), by Country
  • Figure 62. Europe Mebeverine Share (%), by Country
  • Figure 63. MEA Mebeverine Share (%), by Country
  • Figure 64. North America Mebeverine Share (%), by Country
  • Figure 65. Global Mebeverine: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Abbott (United States)
  • Mylan N.V. (United States)
  • Berlin Pharmaceutical Industry Co., Ltd. (Thailand)
  • Eipico Pharmaceutical (Egypt)
  • Sopharma (Bulgaria)
  • USV Private Limited (India)
  • PURE Pharma GmbH & Co. KG (Germany)
  • Pharco Corporation (Egypt)
  • Swiss Pharma Pvt Ltd (India)
  • Dr. Reddy's (India)
Select User Access Type

Key Highlights of Report


Mar 2021 243 Pages 76 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Mebeverine Market Quantitative research analysis
Global Mebeverine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Abdominal Diseases among People " is seen as one of major growth factors of Mebeverine Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Mebeverine Market Report?

Have a Query? Click Here

Other Related Reports

Levobupivacaine Comprehensive Study by Application (Oral Surgery Procedures, Diagnostic And Therapeutic Procedures, Obstetrical Procedures, Others), Patient Type (Adult, Elderly), Contraindication (H...
$ 3750
Apomorphine Hydrochloride Comprehensive Study by Type (Pen Injectors, Infusion Pumps), Application (Parkinson Disease, Erectile Dysfunction) Players and Region - Global Market Outlook to 2026
$ 3500
Eltrombopag Tablet Comprehensive Study by Application (Drugs Stores, Hospital, Other), Treatment (Idiopathic Thrombocytopenic (ITC), Cirrhosis, Hepatitis C Virus (HCV), Severe Aplastic Anemia (SAA)),...
$ 3450
Phenytoin Comprehensive Study by Type (Extend Release Capsule (100 mg, 200 mg and 300 mg), Immediate Release Capsule (30 mg and 100 mg), Chewable Tablet (50 mg), Oral Suspension (125 mg/5mL), Injecta...
$ 3750
Fluphenazine Decanoate Comprehensive Study by Application (Acute Schizophrenia, Chronic Schizophrenia, Others), Sales Channel (Hospital Pharmacy, Retail Pharmacy, Other), End User (Children, Adult) P...
$ 3500
Antiparasitic Drugs Comprehensive Study by Type (Anthelmintics (Benzimidazole, Ivermectin, Pyrantel), Scabicides and Pediculicides (Lindane, Benzyl Benzoate), Antiprotozoals (Chloroquine, Pyrimethami...
$ 3750